Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis

No abstract is available for this paper.

• Publication year

  2013

• Venue

  European Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  2013-07-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00259-013-2482-zPMID 23873003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 診断精度研究のバイアスリスク評価ツールQUADAS－2：a Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies 2 の活用

  2014influential reference
• Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: a review of the literature

  2013cited by this paper
• Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia

  2012cited by this paper
• Prospective evaluation of 68Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study

  2012cited by this paper
• High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours

  2012influential reference
• 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET

  2012influential reference
• Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?

  2012cited by this paper
• Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study

  2012influential reference
• Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours

  2012cited by this paper
• The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors

  2012cited by this paper
• Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours

  2012cited by this paper
• Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis

  2012cited by this paper
• 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors

  2011cited by this paper
• Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study.

  2011cited by this paper
• Role of 68Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours

  2011cited by this paper
• 68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol

  2011influential reference
• ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update

  2011cited by this paper
• QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies

  2011cited by this paper
• 68Ga-DOTA-NOC PET/CT Imaging of Neuroendocrine Tumors: Comparison with 111In-DTPA-Octreotide (OctreoScan®)

  2011influential reference
• Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours

  2011cited by this paper
• Ga-68 DOTATOC PET, Endoscopic Ultrasonography, and Multidetector CT in the Diagnosis of Duodenopancreatic Neuroendocrine Tumors: A Single-Centre Retrospective Study

  2010cited by this paper
• A review on the clinical uses of SPECT/CT

  2010cited by this paper
• NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor

  2010cited by this paper
• 68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors

  2010cited by this paper
• The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy

  2010influential reference
• Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE

  2010cited by this paper
• The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors

  2010influential reference
• A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors

  2009cited by this paper
• Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours

  2009influential reference
• Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy

  2009influential reference
• Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.

  2008cited by this paper
• Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours

  2008cited by this paper
• Investigating and Dealing with Publication and Other Biases

  2008cited by this paper
• Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐DPhe1,Tyr3‐octreotate) and 18F‐FDG

  2008cited by this paper
• One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

  2008cited by this paper
• Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

  2007influential reference
• Bmc Medical Research Methodology Open Access Development of Amstar: a Measurement Tool to Assess the Methodological Quality of Systematic Reviews

  2007cited by this paper
• Nuclear imaging of neuroendocrine tumours.

  2007cited by this paper
• Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours

  2007influential reference
• Imaging of neuroendocrine tumors.

  2006cited by this paper
• Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy

  2006influential reference
• Bmc Medical Research Methodology Open Access Motor Function in Parkinson's Disease and Supranuclear Palsy: Simultaneous Factor Analysis of a Clinical Scale in Several Populations

  2006influential reference
• Systematic reviews in health care : meta-analysis in context

  2001cited by this paper
• Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data

  2001influential reference
• Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome.

  1998cited by this paper
• Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours

  1998cited by this paper
• Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.

  1998cited by this paper
• Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management.

  1997cited by this paper
• Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.

  1997cited by this paper
• Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study.

  1996cited by this paper
• Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison.

  1996cited by this paper
• Somatostatin Receptor Scintigraphy: Its Sensitivity Compared with That of Other Imaging Methods in Detecting Primary and Metastatic Gastrinomas: A Prospective Study

  1996cited by this paper
• Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas.

  1996cited by this paper
• Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison.

  1994cited by this paper
• Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome

  1994cited by this paper
• Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

  1993cited by this paper
• One hundred years after.

  1959cited by this paper
• ORIGINAL ARTICLE DOI: 10.3904/kjim.2010.25.4.386 Role of 68 Ga-DOTATOC PET/CT in the Evaluation of Primary Pulmonary Carcinoids

  year unknowncited by this paper

• Tumores Neuroendocrinos Gastroenteropancreáticos

  2025cites this paper
• Comparison of radiolabeled somatostatin analogs (DOTATATE, DOTANOC, and DOTATOC) in somatostatin receptor (SSTR) imaging for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a narrative literature review

  2025cites this paper
• Rising Incidence of Neuroendocrine Neoplasms in Northern Switzerland—Data From the Cancer Registry

  2025cites this paper
• Response Evaluation Criteria in Grade 1/2 Neuroendocrine Tumors (RECIN).

  2025cites this paper
• PET Beyond FDG: New Era of Oncologic Molecular Targets Using Positron-Emitting Radiotracers.

  2025cites this paper
• 68Ga DOTATATE PET/MR Imaging of Well-Differentiated Primary and Metastatic Liver Neuroendocrine Tumors: Unified Evaluation and Correlations of PET, DCE, DWI, and T2-weighted Images.

  2025cites this paper
• One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging

  2025cites this paper
• Endoscopic Ultrasonography (EUS)-Guided SSTR PET/CT Imaging in the Management of Patients with Small (< 2cm) Gastrointestinal Neuroendocrine Neoplasms: A Multicenter Study

  2025cites this paper
• Experimental approach for optimizing dose regimen of 68 Ga-DOTATATE PET/CT for neuroendocrine tumor (NET) imaging in current high sensitivity scanners: Phantom and Patient Study

  2025cites this paper
• Multimodal Imaging Approach to MEN-1 Syndrome-Associated Tumors

  2025cites this paper
• Outcome prediction of SSTR-RADS-3A and SSTR-RADS-3B lesions in patients with neuroendocrine tumors based on 68Ga-DOTATATE PET/MR

  2024cites this paper
• Diagnostic and Therapeutic Management of Primary Orbital Neuroendocrine Tumors (NETs): Systematic Literature Review and Clinical Case Presentation

  2024cites this paper
• Time-of-Flight PET/CT Imaging of Ga-68-Dotatate: Normal Pattern, SUV Quantification, and Differences from Non-Time-of-Flight Imaging

  2024cites this paper
• Recent developments in the diagnosis of pancreatic neuroendocrine neoplasms

  2024cites this paper
• Radiolabeled Somatostatin Analogs for Cancer Imaging.

  2024cites this paper
• Prevalence of metastases outside the liver and abdominal lymph nodes on 68Ga‐DOTATOC‐PET/CT in patients with small intestinal and pancreatic neuroendocrine tumours

  2024cites this paper
• Investigation of Clinical, Laboratory, Imaging Findings and Histopathological Features of Patients with Gastric Neuroendocrine Cell Hyperplasia

  2024cites this paper
• Two synchronous primary mesenteric neuroendocrine tumors in a patient: a case report

  2024cites this paper
• Neuroendocrine Tumors: Diagnostics.

  2024cites this paper
• Diagnostic performance of various imaging modalities in localizing Ectopic ACTH syndrome: A Systematic review.

  2024cites this paper
• Tomographie par émission de positons en cancérologie digestive

  2024cites this paper
• Real-Life Use of [68Ga]Ga-DOTANOC PET/CT in Confirmed and Suspected NETs from a Prospective 5-Year Electronic Archive at an ENETS Center of Excellence: More Than 2000 Scans in More Than 1500 Patients

  2024cites this paper
• Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms

  2023cites this paper
• Druggability of Targets for Diagnostic Radiopharmaceuticals.

  2023cites this paper
• Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine Tumors

  2023cites this paper
• Portuguese Pancreatic Club Perspectives on Pancreatic Neuroendocrine Neoplasms: Diagnosis and Staging, Associated Genetic Syndromes and Particularities of Their Clinical Approach

  2023cites this paper
• Ga-68 DOTATATE PET/CT in a patient with Zollinger-Ellison syndrome

  2023cites this paper
• Techniques de médecine nucléaire pour l’imagerie et traitement des néoplasies neuroendocrines gastro-entéro-pancréatiques

  2023cites this paper
• Applications of Artificial Intelligence and Radiomics in Molecular Hybrid Imaging and Theragnostics for Neuro-Endocrine Neoplasms (NENs)

  2023cites this paper
• Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms

  2023cites this paper
• PET/CT Imaging in Treatment Planning and Surveillance of Sinonasal Neoplasms

  2023cites this paper
• Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients

  2023cites this paper
• A sheep in wolf's clothing: Castleman disease masquerading as a neuroendocrine tumour

  2023cites this paper
• Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?

  2023cites this paper
• Diagnostic work-up and advancement in the diagnosis of gastroenteropancreatic neuroendocrine neoplasms

  2023cites this paper
• Neuroendokrine Tumoren des Pankreas

  2023cites this paper
• Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging

  2023cites this paper
• Molecular imaging Theranostics of Neuroendocrine Tumors.

  2023cites this paper
• Neuroendocrine neoplasm: Current understanding

  2023cites this paper
• Surgical options for the treatment of neuroendocrine neoplasms of the ampulla of Vater: a reference centre experience.

  2022cites this paper
• Opciones en el tratamiento quirúrgico de la neoplasia neuroendocrina de la ampolla de Váter: experiencia en un centro de referencia

  2022cites this paper
• Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer 

  2022cites this paper
• Theranostics: Nuclear medicine for diagnosis and treatment of cancer

  2022cites this paper
• PET-CT in Clinical Adult Oncology—VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors

  2022cites this paper
• Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms

  2022cites this paper
• Fibromatosis mimicking relapse of a neuroendocrine tumor at 68Ga-DOTATOC positron-emission tomography/computed tomography

  2022cites this paper
• Molecular Imaging of Neuroendocrine Neoplasms.

  2022cites this paper
• Clinical Pharmacology of Radiotheranostics in Oncology

  2022cites this paper
• Theranostics bei gut bis mäßig differenzierten GEP-NEN

  2022cites this paper
• 68Ga-DOTATATE PET/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study

  2022cites this paper
• Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors

  2022cites this paper
• Primary Neuroendocrine Tumors and Primary Neuroendocrine Carcinomas of the Liver: A Proposal for a Multidiscipline Definition.

  2022cites this paper
• Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors

  2022cites this paper
• Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors

  2022cites this paper
• 68Ga‐DOTATOC‐PET/MRI and 11C‐5‐HTP‐PET/MRI are superior to 68Ga‐DOTATOC‐PET/CT for neuroendocrine tumour imaging

  2021cites this paper
• The Quest for an Accurate Functional Tumor Volume with 68Ga-DOTATATE PET/CT

  2021cites this paper
• PET/MR for evaluation of musculoskeletal malignancies

  2021cites this paper
• Neuroendocrine Tumors: Imaging Perspective.

  2021cites this paper
• Functional Imaging and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor

  2021cites this paper
• Application of molecular probes in nuclear imaging of neuroendocrine tumors.

  2021cites this paper
• The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours

  2021cites this paper
• Neuroendocrine Neoplasms (NENs)

  2021cites this paper
• PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology

  2021cites this paper
• Gastrointestinal Stromal Tumors, Neuroendocrine Tumors, and Lymphoma

  2021cites this paper
• Multimodality Imaging Review of Multiple Endocrine Neoplasia.

  2021cites this paper
• The value of 68Gallium‐DOTATATE PET/CT in sinonasal neuroendocrine tumor management: A case series

  2021cites this paper
• Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities

  2021cites this paper
• Current update on imaging for pancreatic neuroendocrine neoplasms

  2021cites this paper
• PET Imaging in Neuro-Endocrine Neoplasms (NEN)

  2021cites this paper
• Algorithm-based approach to hypervascular pancreatic lesions.

  2021cites this paper
• Imaging of Neuroendocrine Tumors

  2021cites this paper
• Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma.

  2021cites this paper
• Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies

  2021cites this paper
• Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms

  2021cites this paper
• Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm.

  2021cites this paper
• 68Ga-DOTA-Peptides PET/CT: Physiological Biodistribution, Variants and Pitfalls

  2021cites this paper
• Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).

  2021cites this paper
• Contribution of pet/mr in muskuloskeletal malignancies.

  2021cites this paper
• 68Ga-DOTATATE PET/CT compared to standard imaging in metastatic neuroendocrine tumors: a more sensitive test to detect liver metastasis?

  2021cites this paper
• An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases

  2021cites this paper
• SPLENIC ARTERY ANEURYSM OR PSEUDOANEURYSM

  2021cites this paper
• Imaging and its Impact on Defining the Oligometastatic State.

  2021cites this paper
• Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.

  2021cites this paper
• Pancreas, Adrenal Glands, and Retroperitoneum

  2021cites this paper
• Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms

  2021cites this paper
• [68Ga]-DOTATATE PET in the Central Nervous System

  2021cites this paper
• PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses

  2021cites this paper
• Long- term outcome of indigenous 177 Lu- DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting

  2020cites this paper
• Advances in the Diagnosis and Management of Gastrinoma

  2020cites this paper
• Primary mesorectal carcinoid tumour, a case report and review of literature

  2020cites this paper
• State-of-the-Art-Bildgebung von neuroendokrinen Tumoren

  2020cites this paper
• Nuclear Imaging of Neuroendocrine Tumors.

  2020cites this paper
• Targeted precision neuroendocrine neoplasms (NEN) surgery may represent an innovative, yet promising, development of surgical procedures to achieve a radical resection of the primary tumour (by intra-operative confirmation of tumour-free margins) and to improve the identification of small sized lesi

  2020cites this paper
• Comparison of 68Ga-DOTANOC with 18F-FDG using PET/MRI imaging in patients with pulmonary tuberculosis

  2020cites this paper
• Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting.

  2020cites this paper
• Imagerie des tumeurs duodénales

  2020cites this paper
• Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis

  2020cites this paper
• Radioguided surgery with 68Ga-DOTATATE for patients with neuroendocrine tumors.

  2020cites this paper
• Evidence-Based PET for Endocrine Tumours and Disorders

  2020cites this paper
• Imaging of an Indeterminate Pancreatic Mass

  2020cites this paper